文献速递心外重症与机械循环支持

连续流左心室辅助装置植入同期瓣膜手术的单中心经验

Concomitant valve procedures in patients undergoing continuous-flow left ventricular assist device implantation: A single-center experience.
PubMed 文献 · J Thorac Cardiovasc Surg · 2019-02-21

本研究回顾单中心526例连续流左心室辅助装置(CF-LVAD)植入患者,其中91例同期行瓣膜手术,435例仅植入装置。两组1、6、12、24个月生存率无显著差异(P=.55),同期瓣膜手术非死亡独立预测因子(HR 1.29,95%CI 0.96-1.74,P=.08)。

要点

  • CF-LVAD植入同期瓣膜手术与仅植入装置者生存率无显著差异。
  • 同期瓣膜手术不是死亡的独立预测因子(HR 1.29,P=.08)。
  • 是否同期处理瓣膜应主要基于临床指征。

核心结论

  • 本中心经验显示,CF-LVAD植入时同期行瓣膜手术与死亡率增加无关。
  • 同期瓣膜手术决策应主要基于该手术的临床指征。

研究设计与样本

  • 91例同期行瓣膜手术(CF-LVAD+瓣膜组),435例仅植入CF-LVAD(仅CF-LVAD组)。
  • 装置包括HeartMate II(n=403)和HeartWare(n=123)。
  • 比较两组术前特征及短期、中期生存率。

主要发现

  • 同期瓣膜手术包括三尖瓣修复13例、主动脉瓣修复或置换19例、二尖瓣修复或置换30例、双瓣修复或置换29例。
  • 仅CF-LVAD组1、6、12、24个月生存率分别为90.3%、81.4%、74.9%、67.4%。
  • CF-LVAD+瓣膜组1、6、12、24个月生存率分别为89.0%、75.8%、70.3%、65.9%(P=.55)。
  • Cox多因素模型显示同期瓣膜手术不是死亡的独立预测因子(HR 1.29,95%CI 0.96-1.74,P=.08)。

临床怎么用

  • CF-LVAD植入患者合并瓣膜病时,可考虑同期行瓣膜手术而不必担心死亡率增加。
  • 同期瓣膜手术的决策应主要依据临床指征。

局限性

  • 单中心回顾性研究,结果可能受中心经验和患者选择偏倚影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Long-term support with continuous-flow left ventricular assist devices (CF-LVADs) has improved the outcomes of patients with end-stage heart failure. However, valve disease management in patients who undergo CF-LVAD implantation remains controversial. The aim of this study was to assess our single-center experience with patients who underwent a concomitant valve procedure during implantation of a CF-LVAD. METHODS: From November 2003 through March 2016, 526 patients underwent primary CF-LVAD implantation with a HeartMate II (St Jude Inc, St Paul, Minn; n = 403) or HeartWare (Medtronic, Minneapolis, Minn; n = 123) device at our center. Of those, 91 underwent a concomitant valve procedure during implantation (CF-LVAD+valve procedure group), whereas 435 did not (CF-LVAD-only group). We compared preoperative characteristics and short-term and mid-term survival rates between these groups. RESULTS: The concomitant valve procedures performed included 13 tricuspid valve repairs, 19 aortic valve repairs or replacements, 30 mitral valve repairs or replacements, and 29 double valve repairs or replacements. Survival rates at 1 month, 6 months, 12 months, and 24 months were 90.3%, 81.4%, 74.9%, and 67.4%, respectively, for the CF-LVAD-only group and 89.0%, 75.8%, 70.3%, and 65.9%, respectively, for the CF-LVAD+valve procedure group (P = .55). The results of Cox regression multivariable modeling showed that performing a concomitant valve procedure was not an independent predictor of mortality (hazard ratio, 1.29; 95% confidence interval, 0.96-1.74; P = .08). CONCLUSIONS: In our experience, performing a concomitant valve procedure during CF-LVAD implantation was not associated with an increased mortality rate. The decision to perform a concomitant valve procedure should be made primarily on the basis of clinical indications for the procedure.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Sugiura T, Kurihara C, Kawabori M, et al. Concomitant valve procedures in patients undergoing continuous-flow left ventricular assist device implantation: A single-center experience. J Thorac Cardiovasc Surg. 2019. PMID: 30904255. doi:10.1016/j.jtcvs.2019.02.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。